{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-020410","form_type":"8-K","ticker":null,"cik":"0000793171","company_name":"Vitro Biopharma, Inc.","filed_at":"2024-05-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.990273+00:00","generated_at":"2026-06-01T17:50:28.510957+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Vitro BioPharma issues $375K convertible notes at 20% OID and warrants in private placement","bullets":["Aggregate principal $375,000; purchase price $300,000 (20% original issue discount); interest 20% per annum.","Notes mature May 16, 2024, extendable to Aug 16, 2024; secured by all company assets.","Warrants exercisable for 5 years; conversion/exercise terms tied to Liquidity Event or $95M fully-diluted valuation.","Issued pursuant to prior securities purchase agreement (Nov 16, 2023); exempt under Section 4(a)(2) of Securities Act."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-020410","json":"https://secwatch.observer/filing/0001493152-24-020410.json","markdown":"https://secwatch.observer/filing/0001493152-24-020410.md","text":"https://secwatch.observer/filing/0001493152-24-020410.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/793171/000149315224020410/0001493152-24-020410-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/793171/000149315224020410/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T17:50:28.510957+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f6a39c252e4c972c5e32ec846409ea28ae17b84","claim":"Vitro Biopharma, Inc. incurred convertible notes of $375,000 aggregate principal amount, issued at $300,000 with 20% original issue discount with accredited investors at 20% per annum, accruing from earlier of maturity date or event of default, due f maturing May 16, 2024, extendable to August 16, 2024; or earlier upon a Liquidity Event.","evidence_excerpt":"On May 13, 2024, Vitro BioPharma, Inc. (the “Company”) issued and sold to accredited investors, in a private placement, (i) senior secured convertible notes (the “Notes”) in the aggregate principal amount of $375,000, for an aggregate purchase price of $300,000 (reflecting a 20% original issue discount), and warrants to purchase shares of common stock of the Company (the “Warrants”), pursuant to a previously disclosed securities purchase agreement, dated November 16, 2023.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/793171/000149315224020410/0001493152-24-020410-index.htm","confidence":0.97,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$375,000 aggregate principal amount, issued at $300,000 with 20% original issue discount"},{"label":"Counterparty","value":"accredited investors"},{"label":"Rate","value":"20% per annum, accruing from earlier of maturity date or event of default, due f"},{"label":"Maturity","value":"May 16, 2024, extendable to August 16, 2024; or earlier upon a Liquidity Event"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"7eee16e9945696b32a56e7cac0c9c0f655c7f7eb","claim":"Vitro Biopharma, Inc. entered into senior secured convertible notes with accredited investors valued at aggregate principal amount of $375,000 (effective 2024-05-13).","evidence_excerpt":"On May 13, 2024, Vitro BioPharma, Inc. (the “Company”) issued and sold to accredited investors, in a private placement, (i) senior secured convertible notes (the “Notes”) in the aggregate principal amount of $375,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/793171/000149315224020410/0001493152-24-020410-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"accredited investors"},{"label":"Value","value":"aggregate principal amount of $375,000"},{"label":"Effective","value":"2024-05-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}